NRAS
Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers
Premium
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
Lung Cancer Panel From PlexBio Receives CE Mark
The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.
Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.